Profile data is unavailable for this security.
About the company
Solara Active Pharma Sciences Limited is an India-based company offering diversified, commercial active pharmaceutical ingredients (APIs) and contract manufacturing services in over 70 countries. The Company operates through the API segment. Its commercial and research and development products include Albendazole, Aprepitant (Antiemetic), Artesunate, Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone HCL (Anxiolytic), Cetirizine Dihydrochloride, Chlorpromazine Hydrochloride, Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Colesevelam Hydrochloride, Cycloserine (Antitubercular), Ethacrynic Acid (Cardiovascular Agent), Hydralazine Hydrochloride (Anti-Hypertensive), Ibuprofen Sodium Dihydrate (Anti-inflammatory), Mesna (Antineoplastic Detoxifying Agent), Mirabegron (OAB Treatment), Pentoxifylline, and others. The Company works with pharmaceutical companies from North America, Europe, and Japan.
- Revenue in INR (TTM)14.07bn
- Net income in INR-3.08bn
- Incorporated2017
- Employees2.36k
- LocationSolara Active Pharma Sciences Ltd3rd & 4th Floor, Batra CentreNo.28, Sardar Patel Road, GuindyCHENNAI 600032IndiaIND
- Phone+91 4 443446700
- Fax+91 4 422350278
- Websitehttps://solara.co.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Windlas Biotech Ltd | 6.00bn | 526.38m | 10.80bn | 1.05k | 20.63 | -- | 16.34 | 1.80 | 25.18 | 25.18 | 286.98 | -- | -- | -- | -- | 5,723,394.00 | -- | -- | -- | -- | 37.06 | -- | 8.77 | -- | -- | 59.55 | -- | -- | 10.12 | -- | 11.91 | -- | -- | -- |
| Bliss GVS Pharma Ltd | 7.57bn | 879.46m | 11.59bn | 763.00 | 13.38 | -- | 10.14 | 1.53 | 8.28 | 8.28 | 71.43 | -- | -- | -- | -- | 9,919,995.00 | -- | 7.72 | -- | 10.13 | 47.73 | 38.59 | 11.88 | 10.80 | -- | 10.26 | -- | 8.26 | 0.553 | 15.07 | 371.13 | 107.42 | 27.16 | -12.94 |
| Lincoln Pharmaceuticals Ltd | 5.51bn | 872.70m | 11.62bn | 1.70k | 13.31 | -- | 11.90 | 2.11 | 43.57 | 43.57 | 274.88 | -- | -- | -- | -- | 3,238,331.00 | -- | 13.75 | -- | 16.82 | 54.00 | 50.74 | 15.85 | 14.11 | -- | 41.54 | -- | 3.94 | 8.09 | 7.13 | 5.11 | 16.06 | 7.60 | 0.00 |
| Syncom Formulations (India) Ltd | 2.50bn | 263.83m | 11.89bn | 799.00 | 37.21 | -- | 38.39 | 4.76 | 0.34 | 0.34 | 3.26 | -- | -- | -- | -- | 3,126,329.00 | -- | 7.69 | -- | 10.30 | 39.33 | 31.92 | 10.56 | 8.73 | -- | 4.72 | -- | -- | 2.09 | 7.17 | 1.42 | 18.34 | 25.48 | -- |
| Kopran Ltd | 5.79bn | 403.74m | 12.84bn | 394.00 | 32.00 | -- | 24.26 | 2.22 | 8.32 | 8.32 | 119.70 | -- | -- | -- | -- | 14,693,070.00 | -- | 8.64 | -- | 12.88 | 35.60 | 34.36 | 6.97 | 8.71 | -- | 36.80 | -- | -- | 15.38 | 11.85 | -55.38 | 5.86 | 39.08 | -- |
| Zota Health Care Ltd | 1.68bn | -100.65m | 12.90bn | 338.00 | -- | -- | 181.74 | 7.69 | -3.95 | -3.95 | 65.73 | -- | -- | -- | -- | 4,961,589.00 | -- | 2.13 | -- | 2.78 | 43.59 | 32.39 | -6.00 | 2.01 | -- | -1.81 | -- | 115.52 | 6.68 | 12.45 | -164.81 | -- | 56.84 | -14.14 |
| Beta Drugs Ltd | 2.56bn | 347.57m | 13.27bn | 315.00 | 38.17 | 9.34 | 28.98 | 5.18 | 36.15 | 36.15 | 266.28 | 147.68 | 1.24 | 4.44 | 3.72 | 8,126,721.00 | 16.85 | -- | 25.36 | -- | 41.88 | -- | 13.58 | -- | 1.43 | 18.21 | 0.098 | -- | 23.54 | -- | 23.73 | -- | -- | -- |
| Hester Biosciences Ltd | 2.93bn | 184.70m | 13.80bn | 693.00 | 71.95 | -- | 35.12 | 4.71 | 22.54 | 22.54 | 352.21 | -- | -- | -- | -- | 4,222,078.00 | -- | 8.22 | -- | 10.27 | 67.10 | 69.31 | 7.00 | 16.15 | -- | 2.15 | -- | 22.67 | 13.23 | 14.30 | -32.28 | 0.7733 | 27.62 | -4.36 |
| Ngl Fine Chem Ltd | 3.17bn | 380.04m | 15.81bn | 343.00 | 41.60 | -- | 31.80 | 4.99 | 61.52 | 61.52 | 513.13 | -- | -- | -- | -- | 9,241,813.00 | -- | 15.74 | -- | 20.73 | 53.94 | 45.27 | 11.99 | 13.43 | -- | 34.92 | -- | 3.47 | -12.42 | 19.17 | -58.92 | 10.23 | 5.65 | -- |
| Solara Active Pharma Sciences Ltd | 14.07bn | -3.08bn | 17.06bn | 2.36k | -- | -- | -- | 1.21 | -85.65 | -85.65 | 390.73 | -- | -- | -- | -- | 5,958,916.00 | -- | 2.68 | -- | 4.10 | 40.47 | 44.49 | -21.88 | 4.58 | -- | -1.67 | -- | 10.10 | 13.83 | 22.61 | 61.86 | -- | 26.23 | -- |
| SMS Pharmaceuticals Ltd | 6.13bn | 360.58m | 17.48bn | 1.10k | 48.44 | -- | 24.16 | 2.85 | 4.26 | 4.26 | 72.40 | -- | -- | -- | -- | 5,597,176.00 | -- | 5.86 | -- | 7.77 | 31.67 | 33.18 | 6.65 | 8.34 | -- | 3.13 | -- | 6.26 | 0.4188 | 2.35 | -111.35 | -- | 28.46 | 3.71 |
| Amrutanjan Health Care Ltd | 3.94bn | 440.09m | 18.57bn | 575.00 | 42.53 | -- | 37.25 | 4.71 | 15.13 | 15.13 | 135.41 | -- | -- | -- | -- | 6,860,612.00 | -- | 17.04 | -- | 21.22 | 49.51 | 54.08 | 11.16 | 13.37 | -- | 341.76 | -- | 17.21 | -6.46 | 11.37 | -40.71 | 14.72 | 23.87 | 10.64 |
| Themis Medicare Ltd | 3.64bn | 452.86m | 19.36bn | 996.00 | 42.82 | -- | 33.80 | 5.32 | 4.91 | 4.91 | 39.49 | -- | -- | -- | -- | 3,655,101.00 | -- | 9.59 | -- | 14.94 | 65.58 | 60.13 | 12.44 | 13.15 | -- | -- | -- | 7.33 | -10.21 | 10.85 | -21.93 | 38.18 | 24.51 | -- |
| Morepen Laboratories Ltd | 16.31bn | 761.19m | 23.82bn | 1.65k | 30.88 | -- | 22.27 | 1.46 | 1.51 | 1.51 | 32.53 | -- | -- | -- | -- | 9,891,111.00 | -- | 7.39 | -- | 13.78 | 35.85 | 32.82 | 4.67 | 5.19 | -- | 27.34 | -- | 0.00 | -8.36 | 18.51 | -61.96 | 5.50 | 11.33 | -- |
Data as of Apr 19 2024. Currency figures normalised to Solara Active Pharma Sciences Ltd's reporting currency: Indian Rupee INR
11.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| First Sentier Investors (Singapore)as of 31 Dec 2023 | 2.10m | 5.83% |
| Think Investments LPas of 30 Sep 2023 | 806.84k | 2.24% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Mar 2024 | 615.00k | 1.71% |
| Route One Investment Co. LPas of 30 Sep 2023 | 480.46k | 1.34% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 125.19k | 0.35% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 120.80k | 0.34% |
| Dimensional Fund Advisors Ltd.as of 29 Feb 2024 | 7.31k | 0.02% |
| Sectoral Asset Management, Inc.as of 31 Jul 2018 | 1.00k | 0.00% |
| DFA Australia Ltd.as of 31 Dec 2023 | 624.00 | 0.00% |
| American Century Investment Management, Inc.as of 04 Apr 2024 | 250.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 11 Apr 2024Source: FactSet Research Systems Inc.
